Full Text pdf - NCI

More documents

Recommendations

Info

ABL KINASE DOMAIN MUTATIONS IN IMATINIB-TREATEDEGYPTIAN PATIENTS with CHRONIC MYELOID LEUKEMIAYasser H. ElNahass 1 , Hossam K. Mahmoud 2 , Fahmy T. Ali 3, Mohamed R. Mohamed 3 Mahmoud M. Said 3Mohamad Abdel Moaty Samra 2 , Mohamed A.M. Ali 3 , Amir SALEM 4 and Wafaa H. ElMetnawy 5Journal of Leukemia, 2013P = 0.003P = 0.011P = 0.01742
ABL KINASE DOMAIN MUTATIONS IN IMATINIB-TREATEDEGYPTIAN PATIENTS with CHRONIC MYELOID LEUKEMIAYasser H. ElNahass 1 , Hossam K. Mahmoud 2 , Fahmy T. Ali3, Mohamed R. Mohamed 3 Mahmoud M. Said 3Mohamad Abdel Moaty Samra2, Mohamed A.M. Ali3, Amir Salem 4 and Wafaa H. ElMetnawy 5Journal of Leukemia, 201343
Page 1 and 2: CML MONITORING INTHE TKI ERAYasser
Page 3 and 4: 2008 WHO CLASSIFICATION OF MPNsPhil
Page 5 and 6: CML Phases5Chronic-phase CML (WHO):
Page 7 and 8: CML: Findings in PBMyelocyteBasophi
Page 9 and 10: Cytogenetic analysisKaryotype:Stand
Page 11 and 12: 11Philadelphia chromosome
Page 13 and 14: 13Iso (17)
Page 15 and 16: Fluorescent In Situ Hybridization(F
Page 17: 17Locations of the breakpoints in t
Page 20 and 21: 20RQ-PCR amplification assays:measu
Page 22 and 23: Use of a conversion factor to conve
Page 24 and 25: ELN 2009: Definitions of ResponseRe
Page 28 and 29: 28The BCR-ABL transcript percentpar
Page 30 and 31: RESISTANCE TO IMATINIB1ry Resistanc
Page 33 and 34: 33Suboptimal response defined by RQ
Page 35 and 36: 13th Congress of the European He
Page 37 and 38: PFS100= 2 log reductions (n=59)
Page 39 and 40: BCR-ABL kinase domain mutations1. D
Page 41: Mutations critical for 2 nd generat
Page 45 and 46: Faster and deeper molecular respons
Page 47 and 48: Predictive Value of Pretreatment BC
Page 49: 49Thank you!

Full Text pdf - NCI

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?